Jones Financial Companies Lllp Grows Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Jones Financial Companies Lllp boosted its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 107.7% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 812 shares of the biopharmaceutical company's stock after buying an additional 421 shares during the quarter. Jones Financial Companies Lllp's holdings in Regeneron Pharmaceuticals were worth $578,000 at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of REGN. CWA Asset Management Group LLC purchased a new stake in shares of Regeneron Pharmaceuticals in the 3rd quarter valued at $298,000. Sigma Planning Corp boosted its position in shares of Regeneron Pharmaceuticals by 4.1% in the 3rd quarter. Sigma Planning Corp now owns 409 shares of the biopharmaceutical company's stock worth $430,000 after purchasing an additional 16 shares in the last quarter. Baker Avenue Asset Management LP purchased a new position in shares of Regeneron Pharmaceuticals in the 3rd quarter worth about $707,000. Ashton Thomas Securities LLC increased its holdings in shares of Regeneron Pharmaceuticals by 10.5% in the 3rd quarter. Ashton Thomas Securities LLC now owns 790 shares of the biopharmaceutical company's stock worth $830,000 after purchasing an additional 75 shares in the last quarter. Finally, Peregrine Asset Advisers Inc. purchased a new stake in Regeneron Pharmaceuticals during the 3rd quarter valued at $424,000. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several analysts recently issued reports on the company. Wells Fargo & Company decreased their target price on Regeneron Pharmaceuticals from $1,050.00 to $900.00 and set an "overweight" rating on the stock in a research note on Friday, January 10th. Leerink Partners upgraded Regeneron Pharmaceuticals from a "market perform" rating to an "outperform" rating and increased their price objective for the company from $762.00 to $834.00 in a report on Wednesday, February 5th. Bernstein Bank reduced their price target on shares of Regeneron Pharmaceuticals from $1,070.00 to $1,000.00 in a research report on Tuesday, February 4th. Wolfe Research began coverage on shares of Regeneron Pharmaceuticals in a report on Friday, November 15th. They issued an "outperform" rating and a $1,150.00 price objective for the company. Finally, Piper Sandler dropped their target price on shares of Regeneron Pharmaceuticals from $1,195.00 to $1,013.00 and set an "overweight" rating on the stock in a research report on Monday, January 27th. One analyst has rated the stock with a sell rating, six have assigned a hold rating, seventeen have issued a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $973.13.

Remove Ads

Regeneron Pharmaceuticals Stock Down 3.6 %

NASDAQ:REGN traded down $26.92 on Tuesday, reaching $717.91. 564,559 shares of the stock traded hands, compared to its average volume of 617,224. The company has a current ratio of 4.73, a quick ratio of 3.95 and a debt-to-equity ratio of 0.09. The company has a market capitalization of $78.49 billion, a price-to-earnings ratio of 18.76, a PEG ratio of 2.34 and a beta of 0.27. The company's fifty day simple moving average is $696.96 and its 200 day simple moving average is $845.58. Regeneron Pharmaceuticals, Inc. has a 12 month low of $642.00 and a 12 month high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last released its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share (EPS) for the quarter, beating the consensus estimate of $11.21 by $0.86. The firm had revenue of $3.79 billion for the quarter, compared to analysts' expectations of $3.76 billion. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The company's revenue for the quarter was up 10.3% compared to the same quarter last year. During the same quarter last year, the business posted $11.86 earnings per share. Equities analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Thursday, March 20th. Investors of record on Thursday, February 20th will be given a $0.88 dividend. The ex-dividend date of this dividend is Thursday, February 20th. This represents a $3.52 dividend on an annualized basis and a yield of 0.49%. Regeneron Pharmaceuticals's dividend payout ratio is currently 2.30%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.